Exelixis Inc. (EXEL)
EXEL or LQDA: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
Exelixis Inc. NASDAQ: EXEL stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94 cents, which was 27% above the consensus estimate and 95% higher on a year-over-year (YoY) basis.
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.55 per share a year ago.
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy Exelixis (EXEL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
